AKY-1189 is a novel Nectin-4 targeted radiopharmaceutical product candidate demonstrating substantial tumor uptake across several solid tumor types and is progressing in human development as a therapeutic agent AKY-1189 was engineered to deliver actinium-225 directly to tumors while…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.